NOVEL REGIMENS FOR TREATMENT OF PSORIASIS

Abstract

Psoriasis is a dermatological disorder consists of   abnormal multiplied skin cells   than normal one. It causes the thickness of skin is increased and forms a   red patches and white scales in the lesion. The disease causing several adverse problems in patient's i.e. adverse physical and mental conditions that are same to   malignancies, heart disorder, diabetes mellitus, and depression. This review focus on the novel therapies for psoriasis that have emerged recently. It contains different classes of drugs (local, systemic) with different mechanism of action. Psoriasis cure rate is very low, so this regimens goal is to relieve symptoms as long as possible with a good benefit/risk ratio. In this review, the new regimens that target pathways and other steps in the pathogenesis of psoriasis are discussed, including IL12/IL-23, IL-17, IL-22, TNF- , JAK inhibitor etc.The prevalence of disease in worldwide is 0.6 to 4.8%. Cyclosporine and methotrexate are the example of systemic treatment regimen for the management of psoriasis but their toxicity is very high, nephrotoxicity, hepatotoxicity and pulmonary fibrosis are the toxicities of methotrexate and cyclosporine. But in the case of novel regimens the toxicity is very low as compared to existing regimens. This article was designed to compare the treatment efficacy of novel regimen with already available treatment options for psoriasis.